SNY250117P80000
- 0.00
- 0.000.00%
Sanofi Newsroom
IGM Bio Plunges as Wall Street Downgrades on Portfolio Shakeup
Price Over Earnings Overview: Sanofi
Travel Vaccines Industry Forecast 2024-2032, Featuring Strategic Analysis of GlaxoSmithKline, Merck & Co, Sanofi, Pfizer, CSL Limited, Bavarian Nordic, Roche, Abbott Labs, AstraZeneca, Janssen Pharma & More
Sanofi Reports Positive Results From Trial of Multiple Myeloma Drug Candidate
IGM to Slash 73% of Workforce, Halt Two Drug Programs
Vir Biotech Upgraded at Morgan Stanley on Cancer Drug Data
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
Sanofi's Sarclisa Subcutaneous Formulation Achieves Co-Primary Endpoints In IRAKLIA Phase 3 Trial For Multiple Myeloma Treatment
Sanofi (SNY.US) announced that the anti-CD38 monoclonal antibody has been approved in China for the treatment of multiple myeloma.
Sanofi (SNY.US) has just announced that the injection of Aishetuximab has been approved by China's National Medical Products Administration (NMPA) for market launch.
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies
Vir Jumps After Phase 1 Data for Sanofi-partnered Cancer Drug Technology
Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for Use of AntiClastic Antisense Platform With Sanofi
Sanofi Down 10% in 3 Months: How Should You Play the Stock?
Express News | Refile-Buzz-Obesity Drugs, M&a Among Key Pharma Drivers for 2025, Berenberg Says
Berenberg Bank Sticks to Their Buy Rating for Sanofi (SNYNF)
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Cencora (COR)
Bird Flu Claims First U.S. Life in Louisiana
'LDH Reports First U.S. H5N1-Related Human Death' - Louisiana Department Of Health
Semaglutides Market Research Report 2024-2028 & 2033 Featuring Major Players, Pfizer, Roche, Merck, AbbVie, and Sanofi
Sanofi (SNY.US) has received approval for clinical trials of its novel dual antibody drug in China.
Recently, CDE announced that the Class 1 new drug SAR442970 injection declared by Sanofi (SNY.US) has obtained implied approval for clinical trials.